Sort
40,608 grants matching “prostate cancer”
Development of Angiogenesis Inhibitors
$440,267William Douglas Figg · Division Of Clinical Sciences - Nci · ZIA · FY2012 · CA
Development of Drugs That Target Prostate Cancer
$440,267William Douglas Figg · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
PLCO EEMS and Extended Follow Up
$440,245Steven Moore · Division Of Cancer Epidemiology And Genetics · ZIA · FY2024 · CA
Novel Therapeutic Strategies to Co-Target Undifferentiated Prostate Cancer (PCa) Stem Cells and Bulk PCa Cells
$440,230Dean G Tang · Roswell Park Cancer Institute Corp · R01 · FY2020 · CA
Biomarkers, mechanisms and modulation of oxidative stress associated risk factors in carcinogenesis
$440,000Yun Rose Li · Beckman Research Institute/City Of Hope · DP5 · FY2022 · OD
Function of the METTL3-NUP93 complex-mediated nuclear export of m6A-modified mRNAs in castration-resistant prostate cancer.
$439,997Kexin Xu · University Of Texas Hlth Science Center · R01 · FY2024 · CA
The function of cyclin C in tumorigenesis
$439,962Piotr Sicinski · Dana-Farber Cancer Inst · R01 · FY2019 · CA
Comprehensive characterization of prostate stromal gene expression and association with lethal prostate cancer
$439,959Brenda M Birmann · Brigham And Women'S Hospital · R37 · FY2024 · CA
Atlases to Report and Correlate Radiotherapy Dose Distributions with Outcomes
$439,902Andrew Jackson · Sloan-Kettering Inst Can Research · R01 · FY2011 · CA
A Serum Marker for Aggressive Prostate Cancer
$439,850Donna M Peehl · Stanford University · R01 · FY2009 · CA
Biomarker Reference Laboratory, EDRN
$439,835William E. Grizzle · University Of Alabama At Birmingham · U24 · FY2007 · CA
Molecular Pathology of Cancer
$439,833Michael Emmert-Buck · Division Of Clinical Sciences - Nci · ZIA · FY2012 · CA
Project 3 Topological mapping of chromatin architectures for hormone-independent gene transcription
$439,821Victor Jin · University Of Texas Hlth Science Center · U54 · FY2018 · CA
Cell Survival Advantage in Cadmium Induced Carcinogenesis
$439,782Chendil Damodaran · Texas A&M University Health Science Ctr · R01 · FY2025 · ES
Elucidating the Molecular Basis of Cellular Metal Stress by using Mass Spectrometry-Based Proteomic Methods
$439,733Katherine J. Franz · Duke University · R01 · FY2022 · GM
Predictive Neurophysiological Biomarkers for Risk of AlzheimerâÃÂÃÂs Disease (AD) and Related Dementia (ADRD) Induced Cognitive Impairment in Sino-US Cohorts
$439,685Yang Jiang · University Of Kentucky · R56 · FY2018 · AG
The Role of Carboxypeptidase E in Cancer
$439,593Yoke P Loh · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2009 · HD
Molecular and Cell Biology
$439,553Joseph R Landolph · University Of Southern California · P30 · FY2010 · CA
Statistical Genetics and Genomics for Epidemiologic Research
$439,543James Dai · Fred Hutchinson Cancer Research Center · R01 · FY2018 · CA
Novel Full-length Cdnas Differentially Expressed During Hematopoietic Commitment
$439,466Griffin P. Rodgers · Diabetes, Digestive, Kidney Diseases · Z01 · FY2007 · DK
Development of SHP2 inhibitors for targeted anti-cancer therapy
$439,449Zhong-Yin Zhang · Purdue University · R01 · FY2019 · CA
Regulation of Mitochondrial Metabolism by Tyr-phosphorylated ATP Synthase Alpha-Subunit and its Therapeutic Implications in Prostate Cancer
$439,433Nupam P Mahajan · Washington University · R01 · FY2024 · CA
Accurate MR-based PET Attenuation Correction for Quantitative Clinical Trials
$439,398Raymond F Muzic · Case Western Reserve University · R01 · FY2019 · CA
Defining Response and Resistance to PI3K and AR inhibition in Prostate Cancer
$439,351Brett Stewart Carver · Sloan-Kettering Inst Can Research · R01 · FY2017 · CA
Defining Response and Resistance to PI3K and AR inhibition in Prostate Cancer
$439,351Brett Stewart Carver · Sloan-Kettering Inst Can Research · R01 · FY2018 · CA